Third-line Therapy for Chronic Myeloid Leukemia: Current Status and Future Directions

Overview

Journal J Hematol Oncol

Publisher Biomed Central

Specialties Hematology
Oncology

Date 2021 Mar 19

PMID 33736651

Citations 42

Authors

Jorge Cortes

Fabian Lang

Affiliations

Soon will be listed here.

Abstract

Chronic myeloid leukemia (CML) is driven by the BCR-ABL1 fusion protein, formed by a translocation between chromosomes 9 and 22 that creates the Philadelphia chromosome. The BCR-ABL1 fusion protein is an optimal target for tyrosine kinase inhibitors (TKIs) that aim for the adenosine triphosphate (ATP) binding site of ABL1. While these drugs have greatly improved the prognosis for CML, many patients ultimately fail treatment, some requiring multiple lines of TKI therapy. Mutations can occur in the ATP binding site of ABL1, causing resistance by preventing the binding of many of these drugs and leaving patients with limited treatment options. The approved TKIs are also associated with adverse effects that may lead to treatment discontinuation in some patients. Efficacy decreases with each progressive line of therapy; data suggest little clinical benefit of treatment with a third-line (3L), second-generation tyrosine kinase inhibitor (2GTKI) after failure of a first-generation TKI and a 2GTKI. Novel treatment options are needed for the patient population that requires treatment in the 3L setting and beyond. This review highlights the need for clear guidelines and new therapies for patients requiring 3L treatment and beyond.

Citing Articles

CDK8/19 inhibition attenuates G1 arrest induced by BCR-ABL antagonists and accelerates death of chronic myelogenous leukemia cells.

Khamidullina A, Yastrebova M, Bruter A, Nuzhina J, Vorobyeva N, Khrustaleva A Cell Death Discov. 2025; 11(1):62.

PMID: 39955308 PMC: 11830074. DOI: 10.1038/s41420-025-02339-6.

Chiglitazar diminishes the warburg effect through PPARγ/mTOR/PKM2 and increases the sensitivity of imatinib in chronic myeloid leukemia.

Duan H, Lai Q, Jiang Y, Yang L, Deng M, Lin Z Exp Hematol Oncol. 2024; 13(1):121.

PMID: 39696470 PMC: 11657277. DOI: 10.1186/s40164-024-00589-1.

Ponatinib: A Review of the History of Medicinal Chemistry behind Its Development.

Nascimento M, Moura S, Parra L, Vasconcellos V, Costa G, Leite D Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39459001 PMC: 11510555. DOI: 10.3390/ph17101361.

Recent developments in receptor tyrosine kinase inhibitors: A promising mainstay in targeted cancer therapy.

Kumar R, Goel H, Solanki R, Rawat L, Tabasum S, Tanwar P Med Drug Discov. 2024; 23.

PMID: 39281823 PMC: 11393807. DOI: 10.1016/j.medidd.2024.100195.

FDA Approval Summary: Asciminib for Ph+ CML in Chronic Phase Treated with Two or More Tyrosine Kinase Inhibitors and for the T315I Mutation.

Pamuk G, Chow E, Ionan A, Chen H, Lee S, Hsu V Clin Cancer Res. 2024; 30(19):4266-4271.

PMID: 39088257 PMC: 11444873. DOI: 10.1158/1078-0432.CCR-24-1086.

References

Soverini S, Bassan R, Lion T . Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges. J Hematol Oncol. 2019; 12(1):39. PMC: 6480772. DOI: 10.1186/s13045-019-0729-2. View

Hochhaus A, Saussele S, Rosti G, Mahon F, Janssen J, Hjorth-Hansen H . Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28(suppl_4):iv41-iv51. DOI: 10.1093/annonc/mdx219. View

Soverini S, Branford S, Nicolini F, Talpaz M, Deininger M, Martinelli G . Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leuk Res. 2013; 38(1):10-20. DOI: 10.1016/j.leukres.2013.09.011. View

Faderl S, Talpaz M, Estrov Z, OBrien S, Kurzrock R, Kantarjian H . The biology of chronic myeloid leukemia. N Engl J Med. 1999; 341(3):164-72. DOI: 10.1056/NEJM199907153410306. View

Cortes J, Jabbour E, Daley G, OBrien S, Verstovsek S, Ferrajoli A . Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib. Cancer. 2007; 110(6):1295-302. DOI: 10.1002/cncr.22901. View

Jabbour E, Kantarjian H . Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020; 95(6):691-709. DOI: 10.1002/ajh.25792. View

Antelope O, Vellore N, Pomicter A, Patel A, Van Scoyk A, Clair P . BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in Philadelphia chromosome-positive leukemia. Exp Hematol. 2019; 77:36-40.e2. PMC: 6803074. DOI: 10.1016/j.exphem.2019.08.007. View

Hochhaus A, Saglio G, Hughes T, Larson R, Kim D, Issaragrisil S . Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016; 30(5):1044-54. PMC: 4858585. DOI: 10.1038/leu.2016.5. View

Zhou H, Mak P, Mu H, Mak D, Zeng Z, Cortes J . Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo. Leukemia. 2017; 31(10):2065-2074. PMC: 5628102. DOI: 10.1038/leu.2017.87. View

10.

Zabriskie M, Eide C, Tantravahi S, Vellore N, Estrada J, Nicolini F . BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 2014; 26(3):428-442. PMC: 4160372. DOI: 10.1016/j.ccr.2014.07.006. View

11.

Manley P, Barys L, Cowan-Jacob S . The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. Leuk Res. 2020; 98:106458. DOI: 10.1016/j.leukres.2020.106458. View

12.

Westerweel P, Te Boekhorst P, Levin M, Cornelissen J . New Approaches and Treatment Combinations for the Management of Chronic Myeloid Leukemia. Front Oncol. 2019; 9:665. PMC: 6691769. DOI: 10.3389/fonc.2019.00665. View

13.

Naka K, Hoshii T, Muraguchi T, Tadokoro Y, Ooshio T, Kondo Y . TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature. 2010; 463(7281):676-80. DOI: 10.1038/nature08734. View

14.

Cortes J, Lipton J, Rea D, Digumarti R, Chuah C, Nanda N . Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood. 2012; 120(13):2573-80. PMC: 4916583. DOI: 10.1182/blood-2012-03-415307. View

15.

Hochhaus A, Baccarani M, Silver R, Schiffer C, Apperley J, Cervantes F . European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020; 34(4):966-984. PMC: 7214240. DOI: 10.1038/s41375-020-0776-2. View

16.

Soverini S, Gnani A, Colarossi S, Castagnetti F, Abruzzese E, Paolini S . Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood. 2009; 114(10):2168-71. DOI: 10.1182/blood-2009-01-197186. View

17.

Cortes J, Rea D, Lipton J . Treatment-free remission with first- and second-generation tyrosine kinase inhibitors. Am J Hematol. 2018; 94(3):346-357. PMC: 6587857. DOI: 10.1002/ajh.25342. View

18.

Corbin A, Agarwal A, Loriaux M, Cortes J, Deininger M, Druker B . Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 2010; 121(1):396-409. PMC: 3007128. DOI: 10.1172/JCI35721. View

19.

Schoepfer J, Jahnke W, Berellini G, Buonamici S, Cotesta S, Cowan-Jacob S . Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1. J Med Chem. 2018; 61(18):8120-8135. DOI: 10.1021/acs.jmedchem.8b01040. View

20.

Ribeiro B, Miranda E, de Albuquerque D, Delamain M, Oliveira-Duarte G, Almeida M . Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors--a single center experience. Clinics (Sao Paulo). 2015; 70(8):550-5. PMC: 4518767. DOI: 10.6061/clinics/2015(08)04. View